Neurobiological Consolidates Phase III Trials To Hasten Viprinex Findings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
By combining data from two structurally similar Phase III trials, Neurobiological Technologies will hasten the pace at which it can make a definitive call on Viprinex (ancrod) and possibly secure a development partner for the ischemic stroke drug